2014-11-26 23:03:10 UTC

CGH Podcast November 2014: Mesalamine Dosage and Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis

A study in the November issue of CGH investigated whether increasing doses of mesalamine reduces concentrations of fecal calprotectin in patients with quiescent ulcerative colitis. Dr. Kuemmerle speaks to co-author Dr. James Lewis of the Perelman School of Medicine at the University of Pennsylvania; Plus, summaries of top stories from this month's issue of GI and Hepatology News.

 

 

Osterman MT, Aberra FN, Cross R. Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis. Clinical Gastroenterology & Hepatology 2014; November 12(11): 1887–1893.e3
Abstract

 

 

 

Duration: 15.20m
Filetype: mp3
Bitrate: 96 KBPS
Frequency: 44100 HZ

 

 

More on Ulcerative Colitis

Submit Your IBD-Related Abstract for the Crohn’s & Colitis Congress

Aug. 16, 2017

Abstracts will be accepted from Aug. 15 through Oct. 31.

Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study

Aug. 1, 2017

This study compares the effectiveness and safety of infliximab and adalimumab in biologic-naive patients with ulcerative colitis, in a nationwide register-based propensity score–matched cohort study.

Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis

Aug. 1, 2017

We review the current evidence to assess the feasibility, value, and impact of integrating continuous clinical response as a patient-reported outcome into routine management of UC.